Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.46 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661841 | 0.87 | F10 (0.48) | F10F2PRSS1ALDH1A1LMNA | |
| SCHEMBL12193281 | 0.87 | F2 (0.45) | F10F2PRSS1ALDH1A1LMNA | |
| SCHEMBL2499245 | 0.87 | F2 (0.45) | F10F2PRSS1ALDH1A1LMNA | |
| SCHEMBL2506034 | 0.87 | F2 (0.45) | F10F2PRSS1ALDH1A1LMNA | |
| SCHEMBL13882334 | 0.84 | F10 (0.46) | F10F2PRSS1LMNAHIF1A | |
| SCHEMBL2504231 | 0.83 | GAA (0.44) | F10LMNAHIF1AGALR3TSHR | |
| SCHEMBL17700759 | 0.81 | F10 (0.40) | F10F2PRSS1ALDH1A1LMNA | |
| SCHEMBL12192903 | 0.81 | OPRD1 (0.45) | F10F2PRSS1ALDH1A1LMNA | |
| SCHEMBL12192906 | 0.81 | OPRD1 (0.45) | F10F2PRSS1ALDH1A1LMNA | |
| SCHEMBL12192897 | 0.81 | F10 (0.48) | F10F2PRSS1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | F10 2043/4885F2 4367/4885PRSS1 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.